Donald I.H. Stewart, President
Don Stewart is the President of Alba Biologics Group, a consulting company providing expertise on drug candidate evaluation, development
and manufacturing strategies.
Dr. Stewart brings more than 20 years experience in the Biotechnology industry, as well as a background in basic research, to this position.
As the Director Research for Cangene Corporation Dr. Stewart was responsible for company�s Mississauga based research and development group.
Cangene is one of Canada�s leading Biopharmaceutical companies and in his role Dr. Stewart led programs on the development of
monoclonal antibodies and recombinant protein drugs, projects that were conducted both in house and at contract sites.
Dr. Stewart previously gained experience in other aspects of therapeutic drug development while responsible for cGMP manufacturing
for clinical trials, animal efficacy and toxicology studies and also for the conduct of a Phase III clinical trial program
for Cangene�s lead recombinant protein drug substance.
Dr. Stewart studied Biochemistry and Cell Biology graduating with a PhD in 1982 from the University of London, England.
Additional laboratory research experience was obtained as a Post Doctoral Fellow at the University of Alberta from 1982 to 1985.
Major Research Support
- Funding as the Project Principal for 5 separate collaborative research contracts in the total amount of
$10.5 million from the CRTI program of Defense Research Canada. The scope of these projects encompassed the development of
novel antibody drug substances to treat casualties in attacks with biological weapons such as Ebola Virus and Ricin poison
as well as the development of a novel drug substance to mitigate the adverse clinical effects of a tactical nuclear explosion.
These projects were conducted in collaboration with various Government Research Institutes and Academic collaborators in Canada, UK and USA.
- Award, as the Principal investigator, of $1.6 million research grant from the NIH, USA for a project
developing monoclonal antibody diagnostics and drug therapies to a bacteria prevalent in tropical climates with the potential
of being developed as a biological weapon.
The project incorporated research groups in Australia, Bulgaria, Canada, Thailand and the USA.